Clinical Trials Search
Clinical Trial 17865
Study Type: Treatment
Phase of Study: Phase I/II
- Kendra Sweet
SL-401 in Patients with Acute Myeloid Leukemia or Blastic Plasmacytoid Dendritic Cell Neoplasm
The goal of this research study is to find the safest highest dose of SL-401 that can be given to patients with AML or BPDCN. This study will also look at how SL-401 stops or slows leukemia or BPDCN growth and how SL-401 enters and leaves your body. This study will also look at certain proteins in your blood and bone marrow and how the amounts of them might change after receiving SL-401, or might be related to how well SL-401 does or does not function against the cancer.
Primary Objectives: The primary objectives are to determine the maximum tolerated dose (MTD), or the maximum tested dose where multiple dose-limiting toxicities (DLTs) are not observed, of SL-401, and to characterize the safety profile of SL-401 at the MTD or maximum tested dose. Secondary Objectives: The secondary objectives are to characterize the anti-tumor activity, pharmacokinetics (PK), and immunogenicity of SL-401.